Suzetrigine is an orally available pain signal inhibitor that selectively targets the NaV1.8 voltage-gated sodium channel, a genetically validated pain target found on peripheral neurons. NaV1.8 is ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, today we look at ...

Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure ...

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...

NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...